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ABSTRACT  
Background: Patients receiving cancer treatment often have one or more co-morbid conditions that 
are treated pharmacologically. Co-morbidities are recorded in clinical trials usually only at baseline. 
However, co-morbidities evolve and new ones emerge during cancer treatment. The interaction 
between multi-morbidity and cancer recovery is significant but poorly understood.  
Purpose: To investigate the effect of co-morbidities (e.g. cardiovascular and diabetes) and 
medications (e.g. statins, antihypertensives, metformin) on radiotherapy-related toxicity and long-term 
symptoms in order to identify potential risk factors. The possible protective effect of medications such 
as statins or antihypertensives in reducing radiotherapy-related toxicity will also be explored.  
Methods: Two datasets will be linked. 1) CHHiP
1
 (Conventional or Hypofractionated High Dose 
Intensity Modulated Radiotherapy for Prostate Cancer) randomised control trial. CHHiP contains 
pelvic symptoms and radiation-related toxicity reported by patients and clinicians. 2) GP
2
 (General 
Practice) data from RCGP RSC
3
 (Royal College of General Practitioners Research and Surveillance 
Centre). The GP records of CHHiP patients will be extracted, including cardiovascular co-morbidities, 
diabetes and prescription medications. Statistical analysis of the combined dataset will be performed 
in order to investigate the effect. 
Conclusions: Linking two sources of healthcare data is an exciting area of big healthcare data 
research. With limited data in clinical trials (not all clinical trials collect information on co-
morbidities or medications) and limited lengths of follow-up, linking different sources of information 
is increasingly needed to investigate long-term outcomes. With increasing pressures to collect detailed 
information in clinical trials (e.g. co-morbidities, medications), linkage to routinely collected data 
offers the potential to support efficient conduct of clinical trials. 
 
KEY WORDS: Data linkage, Radiotherapy-related side-effects, Late-effects, CHHiP, RCGP RSC, 
Big data 
                                                     
1
 CHHiP: Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer 
2
 GP: General practice  
3
 RCGP RSC: Royal College of General Practitioners Research and Surveillance Centre 
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1 Introduction  
High doses of radiation are needed to cure most common cancers. Radiotherapy is planned 
with a “safety margin” to account for any tumour or patient movement during treatment. This 
inevitably leads to the inclusion of some healthy normal tissue in the treatment target area which can 
lead to radiation damage and side-effects [1]. Modern radiotherapy techniques can conform radiation 
dose more precisely to fit the shape of the cancer. In addition the image-guidance methods make 
treatments more accurate. These methods improve tumour targeting so they have significantly reduced 
toxicity [2, 3]. However, serious adverse-effects and reduced quality of life (QOL) are still observed 
in a small number of patients [4-7]. Dose escalation to improve cancer cure can also increase 
morbidity. Radiation side-effects and symptoms often emerge many months or years after treatment 
(late-effects) and may be difficult to investigate or manage.  
Late-effects are a key concern to oncologists, as 84% of prostate cancer (PCa) patients 
survive at least ten years [8] and avoidance of long-term side-effects remains a clinical challenge. As 
the survival rate is relatively high, PCa is now commonly described as a chronic and slowly 
progressing disease. It is therefore crucial to understand the long-term healthcare needs of this ageing 
population of patients and the impact of co-morbidities in the management of side-effects [9]. PCa is 
the most frequently diagnosed male cancer in the United Kingdom (UK) with almost 50000 new cases 
each year [8]. External beam pelvic radiotherapy (EBRT) alongside surgery is the main form of 
treatment and it is often used in conjunction with hormone therapy [10].  
The most common side-effects of pelvic radiotherapy are those experienced from 
gastrointestinal and genitourinary systems. The most troublesome of the range of early reported short-
term side-effects are dysuria, haematuria, irritation and inflammation of the skin, bowel, bladder or 
rectum. These side-effects are caused directly by irradiation, and they usually improve quickly after 
treatment [5, 11]. Late side-effects occur from 6 months to several years after treatment. The most 
common long-term side-effects include urinary obstruction, incontinence, bowel frequency, proctitis 
and sexual problems [7, 12-14]. These side-effects, similarly to the short-term ones, are also caused 
by damage from the radiation and the resulting vascular changes. However, they are usually long-term 
and therefore have a significant impact on the QOL. Inflammation is closely associated with increased 
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acute toxicity, and is also linked to late toxicity (as consequential late-effects) [15]. The link of long-
term side-effects with short-term is not fully defined but short-term side-effects have been identified 
as a precursor of long-term [16]. For this reason it is important to act as early as possible to prevent 
and reduce side-effects.  
There are two areas of research that are of interest regarding co-morbidities and concomitant 
medications for cancer patients. One is that co-morbidities result in worse health-related outcomes for 
radiotherapy patients [2, 3, 17-20]. A recently completed systematic literature review on radiotherapy 
in diabetic patients identified diabetes as a negative factor and highlighted the need for more research 
[17]. Another stem of evidence leads to the effect of cardiovascular medications and improved late 
toxicity [21-25]. Statins have been found to improve health-related outcomes post-radiotherapy [26-
33]. Evidence suggests that those medications may protect against normal tissue injury caused by 
radiation [27-31].  
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2 Materials and Methods 
2.1 Aims  
The aim of this study is to investigate the effect of co-morbidities (focusing on cardiovascular 
diseases and diabetes) and prescription medications (cardiovascular medications such as statins, 
anticoagulants, heart medications, antihypertensives, erectile dysfunction as well as diabetes 
medications e.g. metformin) on symptoms and radiotherapy-related side-effects in PCa patients. Two 
sources of healthcare data will be pulled together to study long-term symptoms and toxicity in relation 
to co-morbidity. General Practice (GP) medical history will be extracted for CHHiP patients. CHHiP 
(Conventional or Hypofractionated High Dose Intensity Modulated Radiotherapy for Prostate Cancer, 
CRUK/06/16) is a large PCa radiotherapy randomised controlled trial (RCT) [34, 35]. Patients 
recruited to CHHiP were randomised to three different radiotherapy schedules and were monitored 
over time. Therefore, long-term patient reported outcomes (PROs) and clinician recorded 
radiotherapy-related symptoms and toxicity data are available. The focus will be on urinary, rectal and 
sexual symptoms and toxicity. The GP dataset that will be used is a dataset of the Royal College of 
General Practitioners Research and Surveillance Centre (RCGP RSC) [36].  
Using de-identified (irreversibly hashed) NHS numbers (already collected with consent in the 
CHHiP trial), GP records on co-morbidities and prescription medications before, during, and after 
radiotherapy will be retrieved for CHHiP patients. CHHiP prospectively collected longitudinal data on 
radiotherapy-related symptoms and toxicity (follow-up up to 5 years) reported both by patients 
(PROs) and clinicians. Table 1 details the type of data extracted and linked from GP records and 
CHHiP trial. The resulting linked dataset will be used to investigate the effect of co-morbidities and 
concomitant medications on symptoms and radiotherapy-related side-effects. 
2.2 Dataset 
2.2.1 CHHiP clinical trial 
CHHiP (CRUK/06/16, REC reference 04/MRE02/10) trial [34, 35] is conducted by the 
Institute of Cancer Research Clinical Trials and Statistics Unit (ICR-CTSU). It is a dataset of 3216 
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men with PCa recruited from 71 centres in the UK, Republic of Ireland, Switzerland, and New 
Zealand between October 2002 and June 2011. Men were randomised to three different conformal 
Intensity Modulated Radiotherapy (IMRT) dose schedules: the standard schedule of 74Gy (37 
fractions(f)) given over 7.5 weeks, or two hypofractionated and shorter schedules, doses of 60Gy 
(20f) or 57Gy (19f). The trial tested the hypothesis that hypofractionated radiotherapy schedules for 
localised PCa would improve the therapeutic ratio by either improving tumour control or reducing 
normal tissue side-effects.  It demonstrated non-inferiority of the 60Gy/20f schedule (compared to 
74Gy/37f) in terms of biochemical/clinical failure with similar and low rates of toxicity [34, 35].  
Patients were followed-up over time, and short-term and long-term PROs and clinician-
reported radiotherapy-related toxicity data are available. The median follow-up of patients is 62.4 
months (IQR: 53.9 - 77.0). PROs were collected (as previously described elsewhere [37, 38]) with the 
UCLA Prostate Cancer Index (UCLA-PCI) [39], Short Form (SF)-36 [40], and Functional 
Assessment of Cancer Therapy-Prostate (FACT-P) [41] questionnaires. In March 2009 UCLA-PCI, 
FACT-P and  SF-36 were replaced by the Expanded Prostate Cancer Index Composite (EPIC) [42] 
and SF-12 [35]. Clinician reported toxicity data were collected with the Radiation Therapy Oncology 
Group (RTOG) [43], the Late Effects Normal Tissue Toxicity; subjective, objective, management, 
and analytic (LENT/SOMA) [44]. In this study, the focus is on symptoms and toxicity in the three 
health domains (urinary, bowel and sexual) that are most affected by PCa and its treatment.   
Only the UK CHHiP population of patients (N = 3179) will be included in this study. The 
non-UK patients will be excluded because there are no NHS numbers for these patients. Patients from 
recruitment centres in Wales, Scotland and Northern Ireland will be included, even though the RCGP 
RSC contains records from English GPs only. This is to create a nationally representative resource. 
The RCGP RSC is representative of the whole UK population [36]. To evaluate the representativeness 
of the linked subsample, the analysis will include comparisons of linked records to non-linked CHHiP 
patients and to the RCGP RSC population. Another reason to include all the UK CHHiP patients is 
that there are other GP databases (aside from RCGP RSC) that could be linked to CHHiP as a follow-
on from this project. This offers the opportunity to follow-up patients from regions that are not 
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available in RCGP RSC. In addition, GP data may be available in RCGP RSC for some of these 
patients if for example they had previously been registered with an English GP.  
In order to support the linkage of CHHiP to other data sources, NHS numbers (CHI numbers 
in Scotland) were collected. Co-morbidities were recorded at baseline and included diabetes, 
hypertension, inflammatory bowel disease, previous pelvic surgery, symptomatic haemorrhoids and 
previous TURP (transurethral resection of the prostate). With regard to prescription medications, the 
information on α-blockers or anticholinergics taken for bladder symptoms [Yes / No] was recorded. 
Table 2 illustrates the exact CHHiP data that will be used in this project. 
2.2.2 RCGP RSC 
The RCGP RSC [36] has been collecting primary care data in England, and monitoring 
disease trends for almost 60 years. The network of practices currently includes 192 GP practices with 
a total number of about 1.5 million active patients (1.5% of the English population). Data are 
extracted weekly from GP practices in the network, covering the past 6 weeks of data. Every four 
months, a bulk extract is conducted where historical data for all registered patients are extracted. All 
patient personally identifiable data are pseudonymised (de-identified) as close as possible to the point 
of extraction from GP databases. The information that will be extracted from GP records for CHHiP 
patients will include co-morbidities (cardiovascular and diabetes) and medication history taken for 
these conditions before, during and after radiotherapy. Cardiovascular medications such as statins, 
anticoagulants, antihypertensives, heart medications, erectile dysfunction as well as diabetes 
medicines such as metformin will be included. Table 1 summarises the type and time points of data 
extracted from both sources.  RCGP RSC has granted permission to conduct this project (Data request 
RSC_0315). An NHS ethics approval has been obtained from the West of Scotland REC1 
(16/WS/0076).  
2.3 Study design  
The study will be undertaken in the following four stages.  
2.3.1 De-identification (pseudonymisation) of CHHiP data  
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All patient personally identifiable data will be de-identified before the transmission of CHHiP 
data to the University of Surrey. NHS numbers will be hashed, dates of birth will be hashed, and 
postcodes converted into Lower Super Output Areas (LSOAs) at the ICR where the data is held. A 
hashing algorithm called Secure Hash Algorithm 2 with 512 bit hash values (SHA2-512) will be 
applied. NHS numbers and dates of birth in the RCGP RSC database are already hashed using the 
same algorithm. Postcodes have also been converted to LSOAs. This will facilitate the data linking 
process without the need of any member of the research team at the University of Surrey to access the 
patient identifiable information. The SHA2-512 is a cryptographic hashing algorithm approved to de-
identify personal information. It uses asymmetric encryption and is described as a one-way function, 
which means that it is computationally impossible to generate the original data from hashed values, 
even with the use of the secret key used for hashing.  
2.3.2 CHHiP data transmission. 
Data for 3179 UK CHHiP participants, including study ID, recruitment centre, hashed NHS 
numbers, hashed dates of birth, LSOAs, age, randomization group, clinical baseline information such 
as tumour stage, co-morbidities and medications, together with symptoms and radiotherapy-related-
toxicity recorded with PROs and clinician-reported tools (see Table 2) will be transmitted to the 
University of Surrey and stored on a secure server. Access to data will be limited to the research team 
and will be password controlled.  
2.3.3 Data linking. 
First, hashed NHS numbers will be used as a unique key to link the two separate databases. 
For patients that cannot be linked through this method, hashed dates of birth, the LSOA, and possible 
diagnosis of prostate cancer will be explored as a secondary linkage method. The information from 
the RCGP RSC records on the number and type of co-morbid cardiovascular and diabetes conditions 
as well as medications taken by CHHiP patients will be extracted (see Table 1).  
2.3.4 Data analysis. 
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To assess the value of the linked resource, statistical analysis of the effect of co-morbidities 
and medications on patient- and clinician-reported symptoms and radiotherapy-related toxicity will be 
conducted. The number of CHHiP patients with co-morbid conditions and the number and type of 
prescription medications that patients take will be described. Medical history collected as part of the 
CHHiP trial will be compared with that obtained from the RCGP RSC. To investigate the 
representativeness of the linked subsample, the incidence (proportion of patients with co-morbidities 
and medications) in the RCGP RSC linked CHHiP subsample will be compared to the overall CHHiP 
population and to the RCGP RSC population. The occurrence and intensity of symptoms and 
radiotherapy-related toxicity in the RCGP RSC linked CHHiP subsample will also be compared to the 
overall CHHiP population. The toxicity profiles of patients with co-morbidities and medications will 
be compared to these of patients that do not have specific co-morbidities or do not take medications to 
investigate the effect. A detailed data analysis plan is described in Section 2.5.  
2.4 Data dictionary  
A systematic literature review was conducted to gain understanding of which medications and 
co-morbidities interact with radiotherapy, and what their impact on the side-effects from radiotherapy 
may be. The literature review fed into the data dictionary and the RCGP RSC extraction query will be 
based on knowledge gathered during the literature review and consultations with clinicians. The data 
extraction will be defined as follows: 
2.4.1 Co-morbidities and symptoms 
The ontology was developed to extract the relevant co-morbidities and symptoms from the 
RCGP database for CHHiP patients. This allowed a conceptual map of symptoms, investigations, 
administrative codes, and diagnoses that can indicate a case to be built [45]. For instance, a person 
with diabetes may not always have a clear diagnosis code in the GP record, but they might have 
administrative codes (diabetes review) or investigation codes (HbA1c blood test results indicating 
diabetes), from which it can be inferred that the patient is a diabetes case.  
2.4.2 Medications 
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A list of relevant medications was created based on Sections 2 and 6.1 (drugs related to 
cardiovascular system and diabetes) of the British National Formula (BNF) (www.bnf.org). In the 
same way as for co-morbidities and symptoms, the list of medications was first developed, and then 
the list of related codes required for data extraction was derived. 
2.5 Data analysis  
Standard descriptive statistics will be used to review the number of co-morbid conditions and 
prescription medications of CHHiP patients for which RCGP RSC data are available. Baseline 
information on co-morbidities and medications recoded in CHHiP will be used to analyse the 
concurrence between the two data sources. The McNemar test for paired data as well as proportional 
odds logistic regression will be used to assess statistical significance of the difference between co-
morbidities reported in CHHiP and those revealed in RCGP RSC data. A chi-squared (χ2) test will be 
used to compare the incidence (proportions) of co-morbidities in the RCGP RSC linked CHHiP 
subsample and in the overall CHHiP sample and RCGP RSC population.   
Using the information on symptoms and radiotherapy-related toxicity recorded in CHHiP, the 
occurrence and intensity in the overall CHHiP population and in the RCGP RSC linked subsample 
will be described. The homogeneity of the RCGP RSC linked CHHiP subsample will be assessed with 
a χ2 test. Logistic regression will be applied to relate the information on occurrence and intensity of 
symptoms and radiotherapy-related toxicity to co-morbidities and prescription medications. This will 
be done to investigate the effect of co-morbidities and medications on symptoms and toxicity. The 
levels of symptoms and toxicity will be summarised for people with particular co-morbid conditions. 
This information will be compared to people without co-morbidities and to the general CHHiP 
population to assess if patients with co-morbidities have higher or lower toxicity levels. Information 
on particular medications such as statins or ACE-inhibitors taken by patients before, during and after 
radiotherapy will be used to investigate the effect of these medications on symptoms and toxicity. The 
information on each of the medications (by a pharmacological group) will be used as a binary item in 
the logistic regression. The plan of data analysis is illustrated in Figure 1. 
Linking CHHiP data with GP records of patients.  11 
 
Age is a well recognized confounding factor [2, 46], and therefore the modelling of 
radiotherapy-related symptoms and toxicity will be adjusted for age. The regression analysis will also 
be adjusted for the effect of the CHHiP randomisation group. Methods based on multilevel analysis of 
variance (ANOVA) will be used to model the effect of co-morbidities and medications on the 
development of symptoms and toxicity over time. Those methods provide a variance split in the data 
according to the contribution of experimental factors [47]. The effect of co-morbidities or medications 
over time will be isolated and assessed without confounding factors such as age or randomisation 
group. If feasible and accordingly to the success of data linkage, Generalized Estimating Equations 
(GEE) [48] will also be used. This is an approach developed for the longitudinal nested data. It allows 
for the inclusion of categorical as well as continuous variables and for variable selection procedures in 
order to select the best model [49]. Regression parameters can be calculated for each point in time. 
Therefore the effect of co-morbidities and medications on acute symptoms can be compared to that on 
long-term effects.   
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3 Discussion 
EBRT can lead to functional and structural damage that can cause long-term symptoms. The 
accumulation of radiation in the tissues results in DNA damage and changes in the cellular micro-
environment, mainly via cytokines-inflammatory pathways. The process of cell reparation and 
restoration is similar to that of wound healing [50]. However, repetitive injury during the course of 
radiation can lead to scaring which in the long-term manifests as fibrosis, atrophy and vascular 
damage [51, 52]. Potential cellular and vascular changes that impact on the side-effects from 
radiotherapy are not fully explained. The evidence regarding the effect of co-morbidities and 
medications  on these cellular and vascular changes is also conflicting but some studies suggest that 
concomitant medications may affect the inflammatory response induced by radiotherapy. 
Cardiovascular medications change inflammatory responses and microvasculature and it is believed 
that through these mechanisms they impact on radiation toxicity [29, 33].  
Long-term injury from EBRT is a serious concern often limiting treatment. Fibrosis reduces 
the elasticity and vascularisation of tissues and organs such as the bladder or bowel, and this leads to 
lasting side-effects [53-56]. Research shows that the occurrence and severity of long-term side-effects 
depends on multiple treatment factors such as the type of treatment, radiation total dose, dose per 
fraction [17, 57-59] and the type of irradiated tissue [60, 61]. Late side-effects are associated with age, 
baseline patient characteristics and intensity of baseline symptoms and short-term side-effects. Recent 
studies also recognised mechanisms of genetic risk factors [62]. In addition, patients with co-morbid 
conditions are at a higher risk than others [63-65]. Risk of fibrosis is higher in patients with 
hypertension or diabetes due to changes in microvasculature, or with scleroderma due to collagen over 
expression [66]. Despite our increasing knowledge of these risk factors, it is still difficult to predict 
the occurrence of fibrosis and late-effects in patients. However, exploring co-morbidities and 
medication use may be of benefit because of the role that they play during regenerative processes and 
the effect on inflammation, microvascular damage, or hypoxia.  
The research into the risk factors has produced conflicting evidence but some studies show 
that cardiovascular medications taken by patients to control their co-morbidities may reduce 
radiotherapy-related toxicity [21, 23, 24]. The mechanisms are not fully established but it is believed 
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that improving the cardiovascular flow of the healthy tissue surrounding tumours may reduce the 
inflammatory response that is responsible for many of the side-effects, and so those medications may 
protect against normal tissue injury caused by radiation. The evidence to support this association is 
limited and there is a need for more research.  
Data linkage techniques are increasingly being used to create comprehensive datasets that can 
be used to explore specific issues or search for evidence that could not be investigated in the limited 
data available from isolated studies. Despite the clear potential and increasing patient benefit, this 
type of research is still hampered by serious governance and data protection issues. To address patient 
confidentiality concerns, an established method of data linkage has been used. This method has been 
deemed adequate by the NHS Research Ethics Committee who approved the project. Inevitably NHS 
numbers are required for linking large datasets such the two used in this study. However, the method 
of irreversible hashing of NHS numbers that will be applied here, protects patients’ privacy while at 
the same time allowing for effective data linkage. Facilitating data sharing across healthcare settings 
and data linkage across studies is supported by the Department of Health information strategy [67]. 
Some examples of benefits to patients include better planning of NHS resources or improved 
healthcare services as well as improved patient health-related outcomes.  
The RCGP RSC database was used because due to the regular data extractions it is one of the 
most up to date GP databases in the UK. It currently covers 1.5% of the English population but it 
continues to expand its GP network. Based on these values, the estimated number of GP records that 
may be available for CHHiP patients is 50. It is a relatively small number and this could potentially 
hinder the statistical analyses that are planned for this project. This is a serious concern and a 
limitation of this study. There are other GP databases that could be used to extract GP records for 
CHHiP patients so there is potential to build on this project. They could be linked to CHHiP to trace 
more patients and increase the quality of the evidence. In the current project a sufficient statistical 
power may not be reached due to potentially a small proportion of linked patients. However, the 
contribution of this project is still considered important. In particular, the success of the linkage 
process can be investigated. The evidence regarding linking clinical trials and GP data is limited and 
CHHiP has never been used in this kind of research.  
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The systems are not in place to routinely link clinical trials with GP data. However, there are 
clear benefits for health research and clinical practice. They include a support of efficient conduct of 
clinical trials and opportunities for a long-term follow-up even after a clinical trial has ended. The 
information on co-morbidities or prescription medications is important, but not always collected 
within clinical trials. It could therefore be obtained via linkage from other sources. However, in order 
to ensure that the opportunities of data linkage are maximised and that the evidence derived from the 
linked resources is reliable, we need to better understand the requirements and implications of data 
linkage. This project will contribute to the knowledge providing the evidence with regard to risks and 
benefits of linking clinical trials and GP data. The process of GP data extraction will be tested and an 
insight generated on how this combined resource could be used to supplement information collected 
within clinical trials.  
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4 Conclusions  
GP records will be extracted for CHHiP patients to investigate the effect of co-morbidities 
and prescription medications on the development of symptoms and on radiotherapy outcomes. This is 
a truly current approach as in the past the research mainly focused on exploring treatment factors and 
baseline patient characteristics. At present there is only limited evidence on the effect of medications 
taken for co-morbid conditions in cancer patients. Methods of reducing side-effects of radiotherapy by 
pharmacologically protecting normal tissue against damage from radiation have not yet been 
extensively explored.  
The reduction of treatment side-effects has become a key challenge in modern radiotherapy as 
patients survive many years post treatment. The population of cancer patients is ageing and the 
complexity of risk factors for radiotherapy-related side-effects increases due to the high prevalence of 
multi-morbidity. Therefore investigating the effect that co-morbidities and medications taken during 
radiotherapy may have on radiotherapy-related toxicity requires more research. This research is of 
high relevance to patients and could potentially lead to improved health-related outcomes post-
radiotherapy. To optimise the management of people treated with radiotherapy an understanding is 
required of how to account for multi-morbidity and its effect during treatment planning and recovery. 
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Table 1. Illustration of the type of data extracted and linked from A) GP records and B) CHHiP trial 
Source of 
data  
Type of data extracted Timelines 
A)  
RCGP 
RSC GP 
records 
Records of co-morbidities: 
 cardiovascular conditions 
 diabetes 
Records of prescription medications 
 cardiovascular medications such as statins, 
anticoagulants, heart medications, 
antihypertensives, erectile dysfunction 
medications 
 diabetes medications eg. metformin  
 antimuscarinics or alpha blockers 
 rectal steroids 
Records of hospital procedures (if recorded): 
 cystoscopy 
 TURP 
 bladder neck incision 
 salvage prostatectomy 
 hip fracture 
 hip replacement 
 sigmoidoscopy 
 colonoscopy 
 argon laser coagulation 
 hyperbaric oxygen 
 records of prescribed incontinence pads 
Over time: 
 from 3 months before the start of 
radiotherapy 
 during radiotherapy  
 after radiotherapy (all data that is 
available) 
B)  
CHHiP 
clinical 
trial  
Patient and clinician-reported cancer and 
radiotherapy-related function, symptoms, 
bother, QOL and toxicity for the following 
health domains:  
 urinary  
 rectal  
 erectile 
 general health  
 physical function  
 
 
 
 
(Detailed list of tools and specific domains is 
in Table 2)   
Longitudinal, the following time 
points will be extracted: 
 initial assessment - pre-hormone 
therapy (baseline) 
 pre-radiotherapy  
 10 weeks after the start of 
radiotherapy (acute) 
 every 6 months, up to 2 years after 
the start of radiotherapy (long-term) 
 toxicity with RTOG collected 
weekly during radiotherapy and 
then at 10, 12, 18 weeks and 12 
months after radiotherapy.  
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Table 2. Illustration of data extracted from CHHiP dataset to be linked with GP records of CHHiP patients. 
Information type Information retained in the study 
Unique patient ID CHHiP study ID 
 
Start of radiotherapy Date of start of radiotherapy  
 
Personal identifiers for linking NHS numbers (hashed), date of birth (hashed), postcode (converted into Lower Super Output Areas (LSOA))  
 
Randomisation group Standard schedule (control group): 74Gy (37 fractions(f)); hypofractionated schedule 1: 60Gy (20f); hypofractionated 
schedule 2: 57Gy (19f) 
 
Baseline information Recruitment centre, age, tumour stage, co-morbidities, previous TURP, medications  
 
Source Tool Domain of health Timeline Scoring scale  
PROs data 
SF-36 General Health, Physical Function 
Scales 
Initial assessment - pre-hormone (baseline) 
Pre-radiotherapy  
10 weeks after the start of radiotherapy 
(acute) 
Every 6 months after the start of 
radiotherapy. Up to 2 years after 
radiotherapy (long-term). 
Scored on a Likert scale. Scores 
converted to a 0–100 scale (0 
representing worst outcome and 100 
representing best outcome). 
SF-12 
UCLA-PCI Urinary, Bowel and Sexual 
Domains EPIC 
FACT-P Additional Concern Scale (12 PCa 
and treatment specific items) 
Clinician 
reported data 
LENT/ SOM Rectal, Bladder/Urethra, Sexual 
Dysfunction Scales 
Graded 0-4 
RTOG (acute) Bladder and Bowel  Weeks: 1-8,10, 12 and 18 
Graded 0-5 
RTOG (late) Urinary Symptoms: Average 
daytime frequency, Nocturia, 
Incontinence. Bowel Symptoms: 
Frequency, Rectal bleeding. 
Erectile Potency. 
12 months 
 
 
